Home / Technology & Devices (page 41)

Technology & Devices

Arvinas and Merck Collaborate to Study Protein Degradation Technology

Today, private biotechnology company Arvinas LLC announced a multi-year collaboration with Merck, which will focus on multiple disease targets, utilizing Arvinas’ novel technology platform. The companies have entered a strategic collaboration, in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel …

Read More »

Federal Resources Aim to Improve States Utilization of Health Information Technology

The Office of the National Coordinator for Health Information Technology (ONC), through a partnership with the Centers for Medicare & Medicaid Services (CMS), is making available online tools and resources that are designed to help states participating in the State Innovation Models initiative improve health care quality and lower costs. …

Read More »

Caribou Biosciences Raises $11 Million to Advance its CRISPR-Cas9 Technology

California-based Caribou Biosciences, one of the upstart leaders in developing CRISPR-Cas9 technologies for precision cell engineering, has closed an $11 million Series A financing round. The group of investors include pharma giant Novartis, Fidelity Biosciences, Mission Bay Capital, 5 Prime Ventures and an undisclosed strategic partner. Additionally, Dr. Jennifer Doudna, …

Read More »

Myriad and AstraZeneca Expand Companion Diagnostic Collaboration into Lynparza Study in Pancreatic Cancer Patients

Myriad Genetics, Inc. and AstraZeneca have expanded their companion diagnostic collaboration to include the utilization of Myriad’s diagnostic test to identify best responders to AstraZeneca’s investigational pancreatic cancer drug. The companies said that under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used prospectively to identify …

Read More »

Registration Open for Biosimilars 20/20: The Next Five Years

TAMPA, FL, April 1, 2015 – The Specialty Pharma Education Center (SPEC) and Specialty Pharma Journal (SPJ) today announced that registration is now open for Biosimilars 20/20, scheduled for June 3-4, 2015 at The Hub in Philadelphia, PA. Biosimilars 20/20 promises to provide an in-depth look into the future of the …

Read More »

Fujifilm to Acquire Stem Cell Pioneer Cellular Dynamics for $307 Million

Japan’s Fujifilm said that it will pay more than $300 million for Wisconsin-based stem cell developer Cellular Dynamics International (CDI) to strengthen its presence in the regenerative field. The companies announced that they have entered into a definitive agreement, under which Fujifilm will acquire CDI. Fujifilm aims to acquire all …

Read More »

Teva Strengthens its CNS Portfolio with its $3.2 Billion Acquisition of Auspex

Today, Teva Pharmaceutical Industries Ltd. announced that it has agreed to acquire central nervous system (CNS) drug developer Auspex Pharmaceuticals, Inc. for about $3.2 billion. The companies said that they have entered into a definitive merger agreement, under which Teva will commence a tender offer for all of the outstanding …

Read More »

Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech

Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …

Read More »

NCPDP Work Group Seeks Solutions in Response to OIG’s Study on Coupon and Copay Violations

In an effort to address concerns regarding pharmaceutical manufacturers’ coupon and copayment programs and the resulting costs to federal government health programs, the National Council for Prescription Drug Programs’ (NCPDP) task group is pulling together clear guidance around the OIG guidelines. The task group is looking at a variety of …

Read More »

RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …

Read More »